Literature DB >> 16286775

Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia.

R J M Ross1, A Rostami-Hodjegan.   

Abstract

Congenital adrenal hyperplasia (CAH) is one of the commonest inherited diseases. Treatment during childhood is directed towards obtaining normal growth. There is an extensive literature on management of CAH during childhood but little published on how patients should be treated as adults. CAH results in increased adrenocorticotropic hormone levels driving the adrenal to produce cortisol and thereby excessive cortisol precursors which are predominantly androgenic. In normal individuals there is a marked circadian rhythm in cortisol release with the lowest levels occurring shortly after midnight and rising between 02.00 and 03.00 h to peak at around 06.00-08.00 h after waking. The treatment of choice for children with CAH is hydrocortisone three times daily. There is no consensus on treating adults. A recent survey by the UK Society for Endocrinology showed that hydrocortisone was the most popular steroid, followed by dexamethasone and then prednisolone. Sixty percent of respondents used a reverse circadian pattern of glucocorticoid treatment and only 16% used a dose based on weight or surface area. In a recent study we demonstrated that the most important variable determining hydrocortisone bioavailability is weight and we advocated a weight-related dosing regimen monitored using a nomogram for serum cortisol. . (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286775     DOI: 10.1159/000087757

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  7 in total

1.  Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia.

Authors:  Kyriakie Sarafoglou; John H Himes; Jean M Lacey; Brian C Netzel; Ravinder J Singh; Dietrich Matern
Journal:  Horm Res Paediatr       Date:  2010-08-25       Impact factor: 2.852

2.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

Review 3.  [Congenital adrenal hyperplasia and growth hormone deficiency. Special care in transition to adulthood].

Authors:  H G Dörr; C Schöfl
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

4.  Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2008-03       Impact factor: 5.958

5.  Optimizing the Timing of Highest Hydrocortisone Dose in Children and Adolescents With 21-Hydroxylase Deficiency.

Authors:  Mariska A M Schröder; Antonius E van Herwaarden; Paul N Span; Erica L T van den Akker; Gianni Bocca; Sabine E Hannema; Hetty J van der Kamp; Sandra W K de Kort; Christiaan F Mooij; Dina A Schott; Saartje Straetemans; Vera van Tellingen; Janiëlle A van der Velden; Fred C G J Sweep; Hedi L Claahsen-van der Grinten
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

6.  A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.

Authors:  Somya Verma; Carol Vanryzin; Ninet Sinaii; Mimi S Kim; Lynnette K Nieman; Shayna Ravindran; Karim A Calis; Wiebke Arlt; Richard J Ross; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-25       Impact factor: 3.478

Review 7.  Treatment of the Enlarged Clitoris.

Authors:  Martin Kaefer; Richard C Rink
Journal:  Front Pediatr       Date:  2017-08-28       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.